Evaluation of 68Ga- and 177Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET imaging and treatment of metastatic melanoma

Molecular Pharmaceutics

Volumn 12, Issue 6, 2015, Pages 1929-1938

  Beaino, Wissam ^a,b   Nedrow, Jessie R ^a,b   Anderson, Carolyn J ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

gallium 68; LLP2A; lutetium 177; melanoma; PET; VLA 4

Indexed keywords

GALLIUM 68; TETULOMAB TETRAXETAN LUTETIUM LU 177; VERY LATE ACTIVATION ANTIGEN 4; GALLIUM; LUTETIUM; RADIOISOTOPE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BIOLUMINESCENCE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; METASTATIC MELANOMA; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOLID PHASE SYNTHESIS; TUMOR BLOOD FLOW; ANIMAL; C57BL MOUSE; EXPERIMENTAL MELANOMA; MALE; MELANOMA; METABOLISM; METASTASIS; PROCEDURES; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; GALLIUM RADIOISOTOPES; HUMANS; INTEGRIN ALPHA4BETA1; LUTETIUM; MALE; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES;

EID: 84930635344     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp5006917     Document Type: Article

References (44)

1. Lens, M. B.; Dawes, M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma Br J. Dermatol. 2004, 150, 179-185
2. Khan, M. K.; Khan, N.; Almasan, A.; Macklis, R. Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents OncoTargets Ther. 2011, 4, 137-148
3. Garbe, C.; Peris, K.; Hauschild, A.; Saiag, P.; Middleton, M.; Spatz, A.; Grob, J. J.; Malvehy, J.; Newton-Bishop, J.; Stratigos, A.; Pehamberger, H.; Eggermont, A. M. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2012 Eur. J. Cancer 2012, 48, 2375-2390
4. Coit, D. G.; Andtbacka, R.; Bichakjian, C. K.; Dilawari, R. A.; Dimaio, D.; Guild, V.; Halpern, A. C.; Hodi, F. S.; Kashani-Sabet, M.; Lange, J. R.; Lind, A.; Martin, L.; Martini, M. C.; Pruitt, S. K.; Ross, M. I.; Sener, S. F.; Swetter, S. M.; Tanabe, K. K.; Thompson, J. A.; Trisal, V.; Urist, M. M.; Weber, J.; Wong, M. K. Melanoma J. Natl. Compr. Cancer Network 2009, 7, 250-275
5. Shah, D. J.; Dronca, R. S. Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma Mayo Clin. Proc. 2014, 89, 504-519
6. Schwartz, R. N.; Stover, L.; Dutcher, J. Managing toxicities of high-dose interleukin-2 Oncology (Williston Park) 2002, 16, 11-20
7. Dunn, G. P.; Koebel, C. M.; Schreiber, R. D. Interferons, immunity and cancer immunoediting Nat. Rev. Immunol. 2006, 6, 836-848
8. Disis, M. L. Immune regulation of cancer J. Clin. Oncol. 2010, 28, 4531-4538
9. Hodi, F. S.; O'Day, S. J.; McDermott, D. F.; Weber, R. W.; Sosman, J. A.; Haanen, J. B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J. C.; Akerley, W.; van den Eertwegh, A. J.; Lutzky, J.; Lorigan, P.; Vaubel, J. M.; Linette, G. P.; Hogg, D.; Ottensmeier, C. H.; Lebbe, C.; Peschel, C.; Quirt, I.; Clark, J. I.; Wolchok, J. D.; Weber, J. S.; Tian, J.; Yellin, M. J.; Nichol, G. M.; Hoos, A.; Urba, W. J. Improved survival with ipilimumab in patients with metastatic melanoma N. Engl. J. Med. 2010, 363, 711-723
10. Hersh, E. M.; O'Day, S. J.; Powderly, J.; Khan, K. D.; Pavlick, A. C.; Cranmer, L. D.; Samlowski, W. E.; Nichol, G. M.; Yellin, M. J.; Weber, J. S. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma Invest. New Drugs 2011, 29, 489-498
11. Tseng, S. Y.; Otsuji, M.; Gorski, K.; Huang, X.; Slansky, J. E.; Pai, S. I.; Shalabi, A.; Shin, T.; Pardoll, D. M.; Tsuchiya, H. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells J. Exp Med. 2001, 193, 839-846
12. Sznol, M.; Kluger, H. M.; Hodi, F. S.; McDermott, D. F.; Carvajal, R. D.; Lawrence, D. P.; Topalian, S. L.; Atkins, M. B.; Powderly, J. D.; Sharfman, W. H.; Puzanov, I.; Smith, D. C.; Wigginton, J. M.; Kollia, G.; Gupta, A. K.; Sosman, J. A. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538) J. Clin. Oncol. 2013, 31, Suppl Abstract CRA9006
13. O'Day, S. J.; Maio, M.; Chiarion-Sileni, V.; Gajewski, T. F.; Pehamberger, H.; Bondarenko, I. N.; Queirolo, P.; Lundgren, L.; Mikhailov, S.; Roman, L.; Verschraegen, C.; Humphrey, R.; Ibrahim, R.; de Pril, V.; Hoos, A.; Wolchok, J. D. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study Ann. Oncol. 2010, 21, 1712-1717
14. Flaherty, K. T. Chemotherapy and targeted therapy combinations in advanced melanoma Clin. Cancer Res. 2006, 12, 2366s-2370s
15. Satyamoorthy, K.; Li, G.; Gerrero, M. R.; Brose, M. S.; Volpe, P.; Weber, B. L.; Van Belle, P.; Elder, D. E.; Herlyn, M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation Cancer Res. 2003, 63, 756-759
16. Bollag, G.; Hirth, P.; Tsai, J.; Zhang, J.; Ibrahim, P. N.; Cho, H.; Spevak, W.; Zhang, C.; Zhang, Y.; Habets, G.; Burton, E. A.; Wong, B.; Tsang, G.; West, B. L.; Powell, B.; Shellooe, R.; Marimuthu, A.; Nguyen, H.; Zhang, K. Y.; Artis, D. R.; Schlessinger, J.; Su, F.; Higgins, B.; Iyer, R.; D'Andrea, K.; Koehler, A.; Stumm, M.; Lin, P. S.; Lee, R. J.; Grippo, J.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; Chapman, P. B.; Flaherty, K. T.; Xu, X.; Nathanson, K. L.; Nolop, K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 2010, 467, 596-599
17. Young, K.; Minchom, A.; Larkin, J. BRIM-1, 2 and 3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation Future Oncol. 2012, 8, 499-507
18. Chapman, P. B.; Hauschild, A.; Robert, C.; Haanen, J. B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C.; Jouary, T.; Schadendorf, D.; Ribas, A.; O'Day, S. J.; Sosman, J. A.; Kirkwood, J. M.; Eggermont, A. M.; Dreno, B.; Nolop, K.; Li, J.; Nelson, B.; Hou, J.; Lee, R. J.; Flaherty, K. T.; McArthur, G. A. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 2011, 364, 2507-2516
19. Hauschild, A.; Grob, J. J.; Demidov, L. V.; Jouary, T.; Gutzmer, R.; Millward, M.; Rutkowski, P.; Blank, C. U.; Miller, W. H., Jr.; Kaempgen, E.; Martin-Algarra, S.; Karaszewska, B.; Mauch, C.; Chiarion-Sileni, V.; Martin, A. M.; Swann, S.; Haney, P.; Mirakhur, B.; Guckert, M. E.; Goodman, V.; Chapman, P. B. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 2012, 380, 358-365
20. Long, G. V.; Trefzer, U.; Davies, M. A.; Kefford, R. F.; Ascierto, P. A.; Chapman, P. B.; Puzanov, I.; Hauschild, A.; Robert, C.; Algazi, A.; Mortier, L.; Tawbi, H.; Wilhelm, T.; Zimmer, L.; Switzky, J.; Swann, S.; Martin, A. M.; Guckert, M.; Goodman, V.; Streit, M.; Kirkwood, J. M.; Schadendorf, D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial Lancet Oncol. 2012, 13, 1087-1095
21. Villanueva, J.; Vultur, A.; Herlyn, M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options Cancer Res. 2011, 71, 7137-7140
22. Sullivan, R. J.; Flaherty, K. T. Resistance to BRAF-targeted therapy in melanoma Eur. J. Cancer 2013, 49, 1297-1304
23. Kwekkeboom, D. J.; Kam, B. L.; van Essen, M.; Teunissen, J. J.; van Eijck, C. H.; Valkema, R.; de Jong, M.; de Herder, W. W.; Krenning, E. P. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors Endocr.-Relat. Cancer 2010, 17, R53-R73
24. Van Essen, M.; Krenning, E. P.; De Jong, M.; Valkema, R.; Kwekkeboom, D. J. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours Acta Oncol. 2007, 46, 723-734
25. Forrer, F.; Uusijarvi, H.; Storch, D.; Maecke, H. R.; Mueller-Brand, J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC J. Nucl. Med. 2005, 46, 1310-1316
26. Miyake, K.; Hasunuma, Y.; Yagita, H.; Kimoto, M. Requirement for VLA-4 and VLA-5 integrins in lymphoma cells binding to and migration beneath stromal cells in culture J. Cell Biol. 1992, 119, 653-662
27. Juneja, H. S.; Schmalsteig, F. C.; Lee, S.; Chen, J. Vascular cell adhesion molecule-1 and VLA-4 are obligatory adhesion proteins in the heterotypic adherence between human leukemia/lymphoma cells and marrow stromal cells Exp. Hematol. 1993, 21, 444-450
28. Holzmann, B.; Gosslar, U.; Bittner, M. alpha 4 integrins and tumor metastasis Curr. Top Microbiol. Immunol. 1998, 231, 125-141
29. Peng, L.; Liu, R.; Marik, J.; Wang, X.; Takada, Y.; Lam, K. S. Combinatorial chemistry identifies high-affinity peptidomimetics against α4β1 integrin for in vivo tumor imaging Nat. Chem. Biol. 2006, 2, 381-389
30. Beaino, W.; Anderson, C. J. PET Imaging of Very Late Antigen-4 in Melanoma: Comparison of 68Ga- and 64Cu-Labeled NODAGA and CB-TE1A1P-LLP2A Conjugates J. Nucl. Med. 2014, 55, 1856-1863
31. Wadas, T. J.; Eiblmaier, M.; Zheleznyak, A.; Sherman, C. D.; Ferdani, R.; Liang, K.; Achilefu, S.; Anderson, C. J. Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors J. Nucl. Med. 2008, 49, 1819-1827
32. Gourni, E.; Demmer, O.; Schottelius, M.; D'Alessandria, C.; Schulz, S.; Dijkgraaf, I.; Schumacher, U.; Schwaiger, M.; Kessler, H.; Wester, H. J. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent J. Nucl. Med. 2011, 52, 1803-1810
33. Reubi, J. C.; Schar, J. C.; Waser, B.; Wenger, S.; Heppeler, A.; Schmitt, J. S.; Macke, H. R. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur. J. Nucl. Med. 2000, 27, 273-282
34. Corneillie, T. M.; Fisher, A. J.; Meares, C. F. Crystal structures of two complexes of the rare-earth-DOTA-binding antibody 2D12.5: ligand generality from a chiral system J. Am. Chem. Soc. 2003, 125, 15039-15048
35. Kulkarni, H. R.; Prasad, V.; Schuchardt, C.; Baum, R. P. Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose? Recent Results Cancer Res. 2013, 194, 561-566
36. Schadendorf, D.; Gawlik, C.; Haney, U.; Ostmeier, H.; Suter, L.; Czarnetzki, B. M. Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours J. Pathol. 1993, 170, 429-434
37. Hart, I. R.; Birch, M.; Marshall, J. F. Cell adhesion receptor expression during melanoma progression and metastasis Cancer Metastasis Rev. 1991, 10, 115-128
38. Moretti, S.; Martini, L.; Berti, E.; Pinzi, C.; Giannotti, B. Adhesion molecule profile and malignancy of melanocytic lesions Melanoma Res. 1993, 3, 235-239
39. Fani, M.; Del Pozzo, L.; Abiraj, K.; Mansi, R.; Tamma, M. L.; Cescato, R.; Waser, B.; Weber, W. A.; Reubi, J. C.; Maecke, H. R. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference J. Nucl. Med. 2011, 52, 1110-1118
40. Nedrow, J. R.; White, A. G.; Modi, J.; Nguyen, K.; Chang, A. J.; Anderson, C. J. Positron emission tomographic imaging of copper 64- and gallium 68-labeled chelator conjugates of the somatostatin agonist tyr3-octreotate. Mol. Imaging 2014, 13 10.2310/7290.2014.00020.
41. Quinn, T.; Zhang, X.; Miao, Y. Targeted melanoma imaging and therapy with radiolabeled alpha-melanocyte stimulating hormone peptide analogues G. Ital. Dermatol. Venereol. 2010, 145, 245-258
42. Siegrist, W.; Solca, F.; Stutz, S.; Giuffre, L.; Carrel, S.; Girard, J.; Eberle, A. N. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells Cancer Res. 1989, 49, 6352-6358
43. Miao, Y.; Whitener, D.; Feng, W.; Owen, N. K.; Chen, J.; Quinn, T. P. Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues Bioconjugate Chem. 2003, 14, 1177-1184
44. Rosenkranz, A. A.; Slastnikova, T. A.; Durymanov, M. O.; Sobolev, A. S. Malignant melanoma and melanocortin 1 receptor Biochemistry (Mosc) 2013, 78, 1228-1237